TREATMENT OF URACHAL ADENOCARCINOMA — CASE REPORT

**Mekic Abazovic Alma,¹ Sulejmanovic Samra,¹ Sehic-Kozica Erna,¹
Mehic Mirza,² Beculic Hakija,³ Jakovljevic Branislava⁴**

¹ Department of Oncology and Radiotherapy, Cantonal Hospital Zenica, Bosnia and Herzegovina

² Department of Gynecology and Obstetrics, Cantonal Hospital Zenica, Bosnia and Herzegovina

³ Department of Neurosurgery, Cantonal Hospital Zenica, Bosnia and Herzegovina

⁴ Health Institution S. Tetik, Oncological Hospital Banjaluka, Bosnia and Herzegovina

Primljen/Received 28. 05. 2015. god.

Prihvaćen/Accepted 10. 07. 2015. god.

Abstract: We report the case of a urachal adenocarcinoma diagnosed in a 55-year-old patient — presenting with dysuria and bloody urine. After admission to hospital, urethrocystoscopy showed large bleeding mass in prostatic part of urethra. He underwent transurethral resection of prostate and cystectomy, with implantations of JJ stents. Immunohistochemistry revealed urachal adenocarcinoma, a rare type of urogenital carcinoma, presented only in 5% of all cancer types. The patient was treated with dual modality, chemotherapy and radiotherapy.

Keywords: urachal adenocarcinoma, urethrocystoscopy, percutaneous nephrostomy, adjuvant chemotherapy, PET CT.

INTRODUCTION

Urachal adenocarcinomas are rare tumors that likely arise from metaplasia of mucosal surface of prostatic part of urethra or from periurethral glands (1, 2). Other anatomic locations include pseudomembranous, but also penile part of urethra (3). Anatomic location largely determines the histological type of cancer. The incidence of adenocarcinoma is 5%, squamous cell carcinoma 80%, and transitional cell carcinoma 15% (4). Causes include chronic inflammation and venereal infections, most likely human papillomavirus. The rareness of these carcinomas represents a formidable diagnostic challenge because of a poor therapeutic benefit in advanced stages even with aggressive treatment.

CASE REPORT

A 55-year-old patient has been examined by urologist on July of 2012. due to pain in pubic area, dysuria and bloody urine, occasionally followed by urine re-

tention. A clinical diagnosis of hypertrophic neoplasia of prostate was made. Within two weeks, patient was hospitalized because of the obstructive uropathy. The urethrocystoscopy was scheduled and it confirmed large, excessively bleeding mass in prostatic part of urethra that is prominent to the urinary bladder lumen. During hospitalization urgent CT scan was made, and it showed homogenous diverticulous area of 54 x 28 mm in the right lateral wall of the bladder and one on the left wall sized 20 x 14 mm, and enlarged prostate of 60 x 60 mm, with unclear differentiation to the seminal vesicles. Because of the massive haemorrhage, transurethral resection of prostate and cystectomy was made with implantations of JJ stents afterwards. On the first pathohistological review, the suspicion for prostate adenocarcinoma was made, but immunohistochemistry revision was requested, and it confirmed that it was urachal adenocarcinoma deriving from prostatic part of urethra. On the tenth postoperative day, MRI scan (Figure 1 and 2) was performed and showed earlier described areas on CT scan, but also neoplastic infiltrating area of 40 mm in the base of prostatic gland going through the right wall of the bladder, pointing at the rest of the tumor. In addition, right stent was removed, and percutaneous nephrostomy was placed due to right kidney hydronephrosis.

The case was presented to the multidisciplinary team, also Rete Oncologica of Italy-Torino was consulted, and adjuvant chemotherapy (gemcitabin 2100 mg/D1, D8 Cisplatin 150 mg/D1 and 5-FU 2100 mg, Cisplatin 210 mg after progression) and radiotherapy (50 Gy/25 fr) were initiated, during which suprapubic cystostomy was done, resulting in significant clinical improvement within two months and patient's symptoms completely resolved. The patient remained

Figure 1 and 2. Postoperative Magnetic Resonance Imaging of Pelvis (sagittal and axial scans)
(Department of Oncology and Radiotherapy
Cantonal Hospital Zenica, BH)

symptom-free after an adjuvant treatment and was discharged from the hospital. Scheduled reevaluation after two and half months was done and PET CT scan revealed mass of 47 mm infiltrating prostatic part of urethra in width of 28 mm, with diverticulous lesions on the right wall of the urinary bladder of 8 mm, significant retroperitoneal lymphadenomegaly and cystic lesion in 5th liver segment, with rectal abdominal muscle infiltration. Two years after the initial symptoms occurred, patient is in a great amount of pain, on daily opioid patches, has bilateral nephrostomies and on close follow-up protocol because there are no further treatment recommendations.

DISCUSSION

This case illustrates a potential of early recognition of this rare pathology which is critical to institution of appropriate therapy and prevention. Luckily, no missteps were taken, although there was a clinical mislead to prostate cancer because of symptom presenta-

tion. Eventhough right and aggressive treatment measures were taken, clinical and imaging techniques were all indicating aggressive disease and progression over such short period of time, but patient still has ecog of 2/3, two years after; in comparison to the median survival without treatment or with palliation, which is approximately 3 months.

Treatment recommendations for superficial lesions (Tis, T1) is to be managed by transurethral resection, but such are rare (5, 6, 7). Invasive T2 tumours carries a poor prognosis in spite of radical cystoprostatectomy and total urethrectomy. A recent report stratified that extravesical involvement had much worse prognosis than intraurethral disease, with a higher chance of nodal involvement and 5-year survival of only 32%. Advanced carcinomas (T3T4N1-N3) is best treated with a combination of neoadjuvant chemotherapy (MVAC) followed by surgery and irradiation, but those data are consistent only for transitional cell tumours (7, 8). Preoperative MVAC against nontransitional types turned out to be ineffective. Radiotherapy yield poor results. Most common approach is external-beam radiotherapy of 50-60Gy over 6 weeks period. Patients who receive radiation therapy followed by salvage surgery seem to fare worse than if surgery was performed in an integrated fashion. Multimodal therapy with chemoradiation has shown the efficacy of 5-FU, mitomycin C, and cisplatin along with external-beam radiotherapy for squamous cell carcinomas but not for other histologic types (6-10).

CONCLUSION

Combining both modalities is expected to lead to a better outcome in treating urachal adenocarcinomas. In NCCN (National Comprehensive Cancer Network) guidelines there is no recommendation for further treatment because of a poor therapeutic benefit documented in clinical trial after adjuvant chemoradiation for advanced urachal adenocarcinomas.

There is no conflict of interests

Abbreviations

PET — Positron Emission Tomography

CT — Computed Tomography

MRI — Magnetic Resonance Imaging

5-FU — 5-fluorouracil

NCCN — National Comprehensive Cancer Network

MVAC — Methotrexate, vinblastine, doxorubicin, and cisplatin

Sažetak

TRETMAN URAHALNOG KARCINOMA — PRIKAZ SLUČAJA

Mekić Abazović Alma,¹ Sulejmanović Samra,¹ Šehić-Kozica Erna,¹ Mehić Mirza,²
Bečulić Hakija,³ Jakovljević Branislava⁴

¹ Služba za onkologiju i radioterapiju, Kantonalna bolnica Zenica, Bosna i Hercegovina

² Služba za ginekologiju i porodiljstvo, Kantonalna bolnica Zenica, Bosna i Hercegovina

³ Služba za neurohirurgiju, Kantonalna bolnica Zenica, Bosna i Hercegovina

⁴ Zdravstvena ustanova S Tetik, Onkološka bolnica Banja Luka, Bosna i Hercegovina

Prikazali smo slučaj urahalnog karcinoma dijagnostikovanog kod 55-godišnjeg pacijenta koji se manifestovao dizurijom i pojavom krvi u mokraći. Nakon hospitalizacije ureterocistoskopija je pokazala veliku krvareću masu i prostatičnom delu uretre. Načinjena je transuretralna resekcija prostate i cistektomija sa implantacijom JJ stenta. Imunohistohemija je pokazala

urahalni adenokarcinom, redak tip urogenitalnog karcinoma, koji čini samo oko 5% svih tipova karcinoma. Pacijent je lečen dualnim modalitetom, hemoterapijom i radioterapijom.

Ključne reči: urahalni adenokarcinom, uretroscopija, perkutana nefrostomija, adjuvantna hemoradioterapija, PET CT.

REFERENCES

1. Bosset JF, Roelofsen F, Morgan DA, et al. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. *Eur J Cancer* 2003; 39(1): 45–51.
2. Klimant E, Amrkman M. Management of Two Cases of Recurrent Anal Carcinoma. *Case Rep Oncol*. 2013; 6(3): 456–61.
3. Chaux A, Amin M, Cubilla AL, Young RH. Metastatic tumors to the penis: a report of 17 cases and review of the literature. *Int J Surg Pathol*. 2011; 19(5): 597–606.
4. Neuzillet Y. Urothelial prostatic and urethral carcinomas. *Rev Prat*. 2014; 64(10): 1367–8.
5. Chalya PL, Rambau PF, Masalu N, Simbila S. Ten-year surgical experiences with penile cancer at a tertiary care hospital in northwestern Tanzania: a retrospective study of 236 patients. *World J Surg Oncol*. 2015: 13–71.
6. Russel AH, Dalbagni G. Cancer of the urethra. In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, eds. *Comprehensive textbook on genitourinary oncology*. Philadelphia: Lippincott Williams and Wilkins, 2006.
7. Ikeda Y, Yasuda M, Kato T, Yano Y, Kurosaki A, Hasegawa K. Synchronous mucinous metaplasia and neoplasia of the female genital tract with external urethral meatus neoplasm: A case report. *Gynecol Oncol Rep*. 2015; 12: 27–30.
8. Corbishley CM, Rajab RM, Watkin NA. Clinicopathological features of carcinoma of the distal penile urethra. *Semin Diagn Pathol*. 2015; 32(3): 238–44.
9. Gaya JM, Matulay J, Badalato GM, Holder DD, Hruby G, McKiernan J. The role of preoperative prostatic urethral biopsy in clinical decision-making at the time of radical cystectomy. *Can J Urol*. 2014; 21(2): 7228–33.
10. Hu B, Djaladat H. Lymphadenectomy for testicular, penile, upper tract urothelial and urethral cancers. *Curr Opin Urol*. 2015; 25(2): 129–35.

Correspondence to /Autor za korespondenciju

Alma Mekić-Abazović

Department of Oncology and Radiotherapy

Cantonal Hospital Zenica, Crkvice 67

72000 Zenica, Bosnia and Herzegovina;

Phone: +387 32 405 133; +387 32 405 534;

E-mail: dr.alma.kbz@gmail.com